MARKET

KTRA

KTRA

Kintara Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.500
-0.020
-1.32%
Closed 16:00 10/22 EDT
OPEN
1.530
PREV CLOSE
1.520
HIGH
1.530
LOW
1.430
VOLUME
206.97K
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
0.3800
MARKET CAP
35.32M
P/E (TTM)
-1.7194
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study
PR Newswire · 1d ago
Kintara And The Global Coalition For Adaptive Research Execute Agreement For VAL-083's Participation In The GBM AGILE Registrational Study
SAN DIEGO, Oct. 21, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor
Benzinga · 1d ago
KTRA: Merger Complete
By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Since Our Initiation Since our initiation on September 9th, Kintara Therapeutics Inc. (NASDAQ:KTRA) has reported 2020 financial and operational results in a press release and in its 10-K for the fiscal year ending June 30, 2020. The company also announced notification of a Small Business Technology Transfer grant to study
Zacks Small Cap Research · 10/12 11:45
3 “Strong Buy” Healthcare Stocks Under $5 That Could Go Boom
Since 2019, the healthcare sector has been bracing for the wild ride that would be the election year. However, according to some Street pros, 2021 is looking a lot like 2009, and this could actually be a good thing for the space.“[We] think 2021 will play out very similarly to 2009 for the health care
TipRanks · 10/01 19:30
Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced its financial results for the year ended June 30, 2020 and provided a corporate update.
PR Newswire · 09/21 13:30
Kintara Therapeutics reports FY results
Kintara Therapeutics (KTRA): FY GAAP EPS of -$0.87.Cash and cash equivalents of ~2.4M.Press Release
Seekingalpha · 09/21 12:44
KTRA: Two Phase III Ready Assets
We are initiating coverage of Kintara with a current valuation of $4.00 per share. This present value is based on our estimates for a successful Phase III trial for two compounds.
Zacks Small Cap Research · 09/16 16:54
Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million
Kintara Therapeutics, Inc. ("Kintara" or the "Company") (Nasdaq: KTRA) announced today the final closing of its previously announced private placement of Series C Convertible Preferred Stock (the "Preferred Stock") to accredited investors. Including the previously announced
PR Newswire · 09/01 13:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KTRA. Analyze the recent business situations of Kintara Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KTRA stock price target is 4.333 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 14
Institutional Holdings: 258.69K
% Owned: 1.10%
Shares Outstanding: 23.54M
TypeInstitutionsShares
Increased
2
81.49K
New
4
-1.42K
Decreased
1
52.99K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.33%
Pharmaceuticals & Medical Research
+1.41%
Key Executives
Chairman/Independent Director
Robert Hoffman
President/Chief Executive Officer/Director
Saiid Zarrabian
Chief Financial Officer
Scott Praill
Chief Scientific Officer/Director
Dennis Brown
Lead Director
John Bell
Director
John Liatos
Director
Keith Murphy
Independent Director
Robert Toth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KTRA
Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.